AVTX Stock — Avalo Therapeutics Inc.: Cash, EV, Pipeline

Share price

$16.57

Market cap

$888.6M

Cash

$400.3M

Enterprise value

$488.3M

Balance sheet

Cash	$400.3M
Debt	$0.0M
Net cash	$400.3M
Enterprise value	$488.3M
Basic shares	52.9M shares
Fully diluted shares	78.2M shares
Fully diluted market cap	$1,296.1M
Cash per share	$7.57

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading AVTX daily closes…

Loading price history…

Pipeline assets

Abdakibart

Phase 2 · Active Modality: monoclonal antibody (humanized IgG)

Aliases AVTX-009

Target IL-1β

Partnerships Eli Lilly: worldwide exclusive license (via AlmataBio/Leap): up to $70M development/regulatory milestones (incl. $10M Phase 3 first-patient milestone deemed probable at 6/30/26), up to $650M sales milestones, royalties 5-15%; AlmataBio acquisition milestone obligations bought out Q2 2026

Indications

hidradenitis suppurativa (moderate to severe) (Phase 2)

Status note Lead anti-IL-1β mAb. Phase 2 LOTUS trial (NCT06603077) in moderate-to-severe HS completed, topline reported Q2 2026; advancing into registrational Phase 3 program. Company is pursuing additional IL-1β-driven indications (none named).

AVTX-010

Stage not disclosed · Active Modality: monoclonal antibody (long-acting next-generation)

Target IL-1β

Indications

not disclosed (Stage not disclosed)

Status note Long-acting next-generation anti-IL-1β mAb; CMC/manufacturing preparation underway. No trial stage stated.

AVTX-008

Stage not disclosed · Active Modality: fusion protein

Target BTLA (B and T Lymphocyte Attenuator)

Indications

not disclosed (Stage not disclosed)

Status note Fully human B and T Lymphocyte Attenuator agonist fusion protein; no trial stage or indication stated in excerpts.

AVTX-913

Preclinical · Active Modality: nucleotide prodrug

Indications

mitochondrial disorder (Preclinical)

Status note Preclinical asset for treatment of a mitochondrial disorder; no target or indication detail stated.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Braidwell LP	1,629,182	+1,629,182	1.11%	2026-08-14
Logos Global Management	1,150,000	+850,000	0.91%	2026-08-14
Baker Bros. Advisors	550,000	+550,000	0.05%	2026-08-14
Sphera Biotech	232,294	+232,294	0.61%	2026-08-14
RTW Investments	175,000	-681,962	0.03%	2026-08-14
Ikarian Capital	90,183	+90,183	0.27%	2026-08-14
OrbiMed Advisors	0	-475,165	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

AVTX — Avalo Therapeutics Inc.

Balance sheet

Price history

Pipeline assets

Institutional holders